STOCK TITAN
  1. Home
  2. News
  3. OCUL

Ocular Therapeut - OCUL STOCK NEWS

Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical innovator developing sustained-release therapies for retinal diseases and ocular conditions. This page serves as the definitive source for company news, providing investors and professionals with timely updates on clinical advancements, regulatory developments, and corporate milestones.

Access press releases, earnings reports, and analysis of key events impacting OCUL's trajectory. Our curated collection includes updates on AXPAXLI™ clinical trials for wet AMD, DEXTENZA® commercial performance, and pipeline progress across glaucoma and diabetic retinopathy therapies. Discover how the company's proprietary hydrogel platform addresses treatment challenges in ophthalmology.

Bookmark this page for streamlined access to OCUL's latest FDA submissions, partnership announcements, and financial disclosures. Stay informed about developments influencing both near-term performance and long-term growth in ocular therapeutics.

News

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

Rhea-AI Summary
Ocular Therapeutix, Inc. announces significant leadership updates with industry expert Pravin U. Dugel, MD appointed as Executive Chair. Jeffrey S. Heier, MD becomes Chief Scientific Officer, Peter K. Kaiser, MD as Medical Director, and Sanjay Nayak, MBBS, PhD as Chief Strategy Officer. The company aims to become a leader in retina care with a focus on wet AMD programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.99%
Tags
management
-
News

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis

Rhea-AI Summary
AffaMed Therapeutics announces acceptance of DEXTENZA NDA by Singapore Health Sciences Authority for treating ocular inflammation and pain following ophthalmic surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer

Rhea-AI Summary
Ocular Therapeutix, Inc. appoints Steve Meyers as Chief Commercial Officer, showcasing dedication to expanding their drug portfolio for eye-related conditions. Meyers brings over 20 years of commercial experience to drive Ocular's commercial efforts forward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.19%
Tags
management
News

Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

Rhea-AI Summary
Ocular Therapeutix, Inc. announces the initiation of Phase 3 SOL-1 clinical trial for AXPAXLI in wet age-related macular degeneration (AMD). The trial aims to evaluate the efficacy and safety of the treatment, potentially reducing the need for frequent injections and office visits for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
clinical trial
-
News

Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

Rhea-AI Summary
Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced that the U.S. FDA has agreed to a Special Protocol Assessment (SPA) Agreement Modification for the Company’s pivotal Phase 3 SOL clinical trial of AXPAXLI™ for the treatment of wet age-related macular degeneration (wet AMD). The amendment expands eligibility criteria, allowing treatment-naïve wet AMD subjects with visual acuity of approximately 20/80 or better to enroll in the trial. The modification also permits the trial to move forward with a single optimized implant with a drug load of 450 µg of a more soluble form of axitinib, aimed at accelerating the enrollment process and improving drug release synchronization with hydrogel bioresorption.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.98%
Tags
clinical trial
-
News

Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Rhea-AI Summary
Ocular Therapeutix, Inc. (Nasdaq: OCUL) closed a public offering of 35,420,000 shares of its common stock at a price of $3.25 per share, generating approximately $115.1 million in gross proceeds. The company plans to use the net proceeds for the Phase 3 clinical development of AXPAXLI for the treatment of wet AMD and other clinical development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.23%
Tags
offering
News

Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock

Rhea-AI Summary
Ocular Therapeutix™, Inc. (Nasdaq: OCUL) announced the pricing of an underwritten public offering of 30,800,000 shares of its common stock at a public offering price of $3.25 per share for gross proceeds of $100.1 million. The Company has also granted the underwriters a 30-day option to purchase up to an additional 4,620,000 shares. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
offering
-
News

Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock

Rhea-AI Summary
Ocular Therapeutix, Inc. (OCUL) has commenced an underwritten public offering of its common stock, with an option for underwriters to purchase additional shares. The company plans to use the proceeds to fund the Phase 3 clinical development of AXPAXLI for the treatment of wet AMD and support other clinical development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
offering
-
News

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

Rhea-AI Summary
Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its participation in upcoming healthcare conferences including Jefferies London Healthcare Conference, BTIG 3rd Annual Ophthalmology Day, and Piper Sandler 35th Annual Healthcare Conference. Management will be available for investor meetings, and live webcasts of the fireside chats will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.2%
Tags
conferences
News

Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update

Rhea-AI Summary
OCUL: FDA agrees to pivotal trial design for AXPAXLI in wet AMD and non-proliferative diabetic retinopathy. Q3 2023 DEXTENZA revenue grows 26% to $15.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.2%
Tags
earnings
Stock OCUL logo
Ocular Therapeut

Nasdaq:OCUL

OCUL Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

OCUL Stock Data

1.16B
152.15M
1.01%
85.07%
7.58%
Biotechnology
Pharmaceutical Preparations
Link
United States
BEDFORD